| |
Lung cancer without COPD
|
Lung cancer with COPD
|
COPD
|
p-value
|
|---|
|
Number of patients (%)
|
92 (44.4%)
|
115 (55.6%)
|
42
| |
|
Age on randomization, y
|
|
median
|
67.5
|
65.8
|
70
|
p = 0.175
|
|
< 59
|
23 (25%)
|
21 (18.3%)
|
6 (14.3%)
|
|
60–69
|
35 (38%)
|
58 (50.4%)
|
14 (33.3%)
|
|
70+
|
34 (37%)
|
36 (31.3%)
|
22 (52.4%)
|
|
Sex
|
|
Female
|
41 (45%)
|
52 (45%)
|
23 (55%)
|
p = 0.237
|
|
Male
|
51 (55%)
|
63 (55%)
|
19 (45%)
|
|
COPD 2017 classification
|
|
II Moderate (FEV1 50–80%)
| |
99 (86.1%)
|
16 (38%)
|
p < 0.001
|
|
III Severe (FEV1 30–50%)
| |
15 (13%)
|
18 (43%)
|
|
IV Very severe (FEV1 < 30%)
| |
1 (0.9%)
|
8 (19%)
|
|
Steroids
|
|
Oral
|
No info
|
No info
|
4 (9.5%)
| |
|
Inhalation
|
No info
|
No info
|
27 (64.3%)
| |
|
No steroids
| | |
11(26.2%)
| |
|
Smoking status
|
|
Never
|
9 (9.8%)
|
1 (0.9%)
|
3 (7%)
|
p = 0.016
|
|
Former
|
57 (62%)
|
65 (56.5%)
|
29 (69%)
|
|
Current
|
26 (28.2%)
|
49 (42.6%)
|
10 (24%)
|
|
Pack-years smoked among former/current smokers
|
83
|
114
|
39
|
p = 0.008
|
|
< 30
|
47 (57%)
|
44 (39%)
|
11 (29%)
| |
|
30–39
|
16 (20%)
|
28 (25%)
|
10 (26%)
| |
|
40–49
|
4 (5%)
|
20 (18%)
|
11 (29%)
| |
|
50+
|
15 (18%)
|
22 (19%)
|
6 (16%)
| |
|
No information
|
1
| |
1
| |
|
Never smokers
|
9
|
1
|
3
| |
|
Lung cancer histology
|
|
Squamous cell carcinoma
|
35 (38%)
|
69 (60%)
| |
p = 0.001
|
|
Adenocarcinoma
|
57 (62%)
|
46 (40%)
| |
|
Lung cancer stage
|
|
I
|
46 (50%)
|
72 (62.6%)
| |
p = 0.105
|
|
II
|
28 (30%)
|
25 (21.7%)
| |
|
III
|
16 (17%)
|
17 (14.8%)
| |
|
IV
|
2 (3%)
|
1 (0.9%)
| |
|
5-year survival
|
54 (59%)
|
68 (59%)
| |
- Clinical characteristics. FEV forced expiratory volume
